Advertisements


FARE, partners say "discouraged" by ICER review of peanut allergy therapies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 12th, 2019

Aimmune cautions stakeholders on ICER report on treatments for peanut allergy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 11th, 2019

ICER releases draft report on Aimmune, DBV peanut allergy treatments

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 10th, 2019

Aimmune falls 2% after peanut allergy drug gets standard 12 month review

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 18th, 2019

Major Step Forward in Peanut Allergy Treatment

DBV Technologies shares dipped on Monday after the firm announced an update from the FDA. Although it was a positive update for the company, this appears to be a case of “sell the news.”.....»»

Category: blogSource: 247wallstOct 7th, 2019

DBV jumps after FDA accepts peanut allergy patch application

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 4th, 2019

Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential Approval

Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential Approval.....»»

Category: topSource: seekingalphaSep 25th, 2019

Analyst: DBV"s Peanut Allergy Drug Could Outscore Aimmune"s On Safety Front

Aimmune Therapeutics Inc (NASDAQ: AIMT)'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received .....»»

Category: blogSource: benzingaSep 16th, 2019

Good News, Bad News in the War on Peanut Allergy

Aimmune shares dipped on Monday after the FDA's Allergenic Products Advisory Committee voted to support the use of AR101 (Palforzia) in children and teens with peanut allergy......»»

Category: blogSource: 247wallstSep 16th, 2019

Peninsula drug company takes big step toward peanut allergy drug approval

Aimmune Therapeutics Inc.'s quest to sell the first biologic drug to treat peanut allergies won a regulatory advisory committee's blessing Friday, moving the company closer to Food and Drug Administration approval. The action by the nine-member panel do.....»»

Category: topSource: bizjournalsSep 16th, 2019

FDA panel recommending approval of first peanut allergy treatment for kids

An estimated 1.6 million children and teenagers would be eligible for the medication, to be sold as Palforzi.....»»

Category: topSource: usatodaySep 13th, 2019

FDA committee votes to support use of Aimmune"s Palforzia for peanut allergy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

FDA panel votes 8-1 saying Aimmune peanut allergy drug Palforzia is safe

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

FDA panel votes 7-2 saying Aimmune"s peanut allergy drug Palforzia works

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

Aimmune"s stock halted as FDA panel"s decision awaited on peanut allergy treatment

Aimmune Therapeutics Inc.'s stock has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is meeting a.....»»

Category: topSource: marketwatchSep 13th, 2019

Aimmune jumps as FDA materials seen as good sign for peanut allergy treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

FDA to ask panel if Aimmune peanut allergy treatment data support approval

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

Here"s why Aclaris is laying off half of its staff

Aclaris Therapeutics decision to eliminate 86 positions, or roughly 50 percent of its workforce, followed a recently completed "strategic review" that concluded the company should focus on further developing its experimental therapies for immuno-inf.....»»

Category: topSource: bizjournalsSep 10th, 2019

Peanut Allergy Can Be Treated With the Very Thing That Causes It

An estimated 1.8 million children in the U.S. have a potentially life-threatening allergy to peanuts. (According to the National Institutes of Health, little is known about peanut allergies in........»»

Category: blogSource: 247wallstSep 6th, 2019

Diplomat Pharmacy enters exclusive partnership with Allergy Partners

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2019

Revolutionary Peanut Allergy Treatment Is One Step Closer

DBV Tech shares shot up on Thursday after the company announced the submission of paperwork to the FDA for Viaskin Peanut for the treatment of peanut-allergic children......»»

Category: blogSource: 247wallstAug 8th, 2019